Epizyme Financial Statements From 2010 to 2024
| EPZMDelisted Stock | USD 1.47 0.00 0.00% |
Check Epizyme financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Epizyme main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . Epizyme financial statements analysis is a perfect complement when working with Epizyme Valuation or Volatility modules.
Epizyme |
Epizyme Company Current Valuation Analysis
Epizyme's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Epizyme Current Valuation | 334.85 M |
Most of Epizyme's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Epizyme is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Epizyme has a Current Valuation of 334.85 M. This is 97.67% lower than that of the Healthcare sector and 92.79% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 97.99% higher than that of the company.
Epizyme Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Epizyme's current stock value. Our valuation model uses many indicators to compare Epizyme value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Epizyme competition to find correlations between indicators driving Epizyme's intrinsic value. More Info.Epizyme is one of the top stocks in return on equity category among related companies. It is one of the top stocks in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Epizyme by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Epizyme's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Epizyme's earnings, one of the primary drivers of an investment's value.About Epizyme Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Epizyme income statement, its balance sheet, and the statement of cash flows. Epizyme investors use historical funamental indicators, such as Epizyme's revenue or net income, to determine how well the company is positioned to perform in the future. Although Epizyme investors may use each financial statement separately, they are all related. The changes in Epizyme's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Epizyme's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Epizyme Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Epizyme. Please read more on our technical analysis and fundamental analysis pages.
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Epizyme operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 250 people.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Epizyme in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Epizyme's short interest history, or implied volatility extrapolated from Epizyme options trading.
Pair Trading with Epizyme
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Epizyme position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Epizyme will appreciate offsetting losses from the drop in the long position's value.Moving together with Epizyme Stock
| 0.81 | NVO | Novo Nordisk AS Sell-off Trend | PairCorr |
| 0.79 | NONOF | Novo Nordisk AS | PairCorr |
Moving against Epizyme Stock
| 0.86 | ZTLLF | Zonetail | PairCorr |
| 0.75 | VRTX | Vertex Pharmaceuticals Financial Report 6th of May 2024 | PairCorr |
| 0.67 | WXIBF | WuXi Biologics | PairCorr |
| 0.63 | CSLLY | CSL | PairCorr |
| 0.62 | GLABF | Gemina Laboratories | PairCorr |
The ability to find closely correlated positions to Epizyme could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Epizyme when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Epizyme - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Epizyme to buy it.
The correlation of Epizyme is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Epizyme moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Epizyme moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Epizyme can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Epizyme information on this page should be used as a complementary analysis to other Epizyme's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Other Consideration for investing in Epizyme Stock
If you are still planning to invest in Epizyme check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Epizyme's history and understand the potential risks before investing.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |